Related Experiment Video
Updated: Dec 13, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.5K
Progesterone and endometrial cancer
1Université de Paris, Hôpitaux Universitaires Port Royal-Cochin, Gynécologie Endocrinienne, 123 bd du Port Royal, Paris, 75014, France.
Best Practice & Research. Clinical Obstetrics & Gynaecology
|August 1, 2020
Summary
Progestogens, including progesterone, can prevent or treat endometrial hyperplasia and cancer (EC) by counteracting estrogen effects. Micronized progesterone (MP) may be safer for the breast but potentially less effective on the endometrium.
Area of Science:
- Gynecology
- Endocrinology
- Oncology
Background:
- Unopposed estrogen exposure is a known risk factor for endometrial hyperplasia and endometrial cancer (EC).
- Key risk factors for EC include anovulatory cycles, obesity, and insulin resistance.
- Progestogens are crucial in preventing and treating estrogen-induced endometrial pathologies.
Purpose of the Study:
- To review the role of progestogens in managing endometrial hyperplasia and endometrial cancer (EC).
- To compare the endometrial effects of micronized progesterone (MP) versus synthetic progestins in hormone therapy.
Main Methods:
- Review of existing literature on progestogen use in endometrial pathology.
- Analysis of epidemiological data and biopsy studies on micronized progesterone (MP).
Main Results:
- Progestogens, including levonorgestrel intrauterine devices, can effectively treat endometrial hyperplasia, atypical hyperplasia, and well-differentiated EC.
- During menopausal hormone therapy, progestogens protect the endometrium from estrogen's proliferative effects.
- Recent data suggest micronized progesterone (MP) may have a better breast safety profile than synthetic progestins, though its endometrial efficacy is debated.
- Some studies show no increased hyperplasia risk with MP, potentially due to compliance issues.
Conclusions:
- Progestogens are essential for endometrial protection against estrogenic stimulation.
- Micronized progesterone (MP) appears safe for the breast but requires further investigation for optimal endometrial protection compared to synthetic progestins.
- Compliance is a critical factor in the clinical effectiveness of progestogen therapy for endometrial conditions.
Related Concept Videos
01:24Disorders of the Female Reproductive System
3.7K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
3.7K
01:27Ovarian Cycle
2.9K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
2.9K
01:20Proliferative Phase
1.1K
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
1.1K
01:22Hormonal Regulation of the Menstrual Cycle
1.2K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.2K
01:24Gonadal and Placental Hormones
2.6K
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
2.6K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
920
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
920